SUMMARY The efficacy of 1 .0% apraclonidine (para-aminoclonidine) in preventing the rise of intraocular pressure following anterior segment, laser surgery was evaluated in a randomised double-masked study. Ninety-nine consecutive patients requiring laser treatment of the anterior segment were included in the study. They were randomised into two groups, one receiving 1 0% para-aminoclonidine and the other placebo (vehicle of para-aminoclonidine). The drug caused a statistically significant reduction in pressure after the laser treatment without causing clinically significant side effects such as bradycardia or hypotension.
During the past few years a number of investigators have reported that a transient intraocular pressure (1OP) rise may follow any anterior segment laser surgery such as argon laser trabeculoplasty, argon or YAG laser iridotomy, or YAG laser capsulotomy. '4 This rise in IOP appears to be unrelated to the type of therapy, the type of laser used, the total amount of energy delivered, bleeding, or cellular debris that occurs during treatment, or to the degree of inflammation after treatment. The IOP rose despite the use of topical ocular hypotensive or non-steroidal anti-inflammatory agents.'--A rise in pressure following laser procedures is at present being treated with carbonic anhydrase inhibitors, oral hyperosmotic agents, or topical timolol, each of which may have undesirable side effects. Apraclonidine is a topical derivative of clonidine prepared by Alcon Laboratories and has minimal systemic hypotensive effects.' Animal studies have shown that apraclonidine ophthalmic solution produces minimal systemic pharmacotoxic effects.
This study, which is prospective, randomised, and controlled, analyses the efficacy of apraclonidine in preventing a rise in IOP in patients undergoing anterior segment laser procedures, namely, Nd-YAG laser capsulotomy and argon Nd-YAG laser iridotomy.
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Patients and methods
Ninety-nine consecutive patients who underwent anterior segment laser treatment between August 1987 and January 1988 at the Vision Research Foundation, Madras, India, were prospectively studied. The following criteria determined exclusion from participation in the study: (1) active ocular infection or inflammation; (2) any past or present severe ocular pathology apart from cataract and glaucoma; (3) unstable cardiovascular disease which may be adversely affected by an o-adrenergic agonist, such as labile hypertension and history of stroke; (4) any abnormality preventing reliable applanation tonometry; (5) pregnant or nursing women and women of childbearing potential; (6) participation in any other investigational drug study within past 30 days; (7) patients with vision in one eye only; (8) patients taking systemic clonidine.
Approval for the study was obtained from the Ethics and Research Subcommittees of Vision Research Foundation, Madras, India. After informed consent had been obtained, at a prestudy examination a medical history was taken, ocular examination carried out, and heart rate and blood pressure recorded. The patients were then randomly assigned to either treatment (1-0% apraclonidine) or placebo groups (vehicle of apraclonidine). Only one eye of each patient was included in the study. Neither the patient nor the investigator was aware of the treat-884 Efficacy and safety ofapraclonidine in patients undergoing anterior segment laser surgery (Table 2) . Seventy patients underwent the laser iridotomy procedure and 29 required laser capsulotomy ( Table  3 ). The lens status of patients enrolled for laser capsulotomy is given in Table 4 , showing similar distributions between treatment groups (p>0-05). (Table 2) , the mean IOP decreased with apraclonidine treatment and increased with placebo treatment during the three hours following laser therapy ( Fig. 1; p>005 ).
The distribution of IOP changes from the prelaser baseline are shown in 
EFFECTS ON CARDIOVASCUILAR PARAMI I ERS
Clinically significant effects on heart rate or blood pressure were not observed in patients from either treatment group at any time. In the three hours following laser treatment, however, some statistically significant findings unrelated to treatment were observed. The mean heart rate ( Fig. 2) and systolic blood pressure (Fig. 3) were both statistically decreased from the prelaser baseline in both treatment groups (p<0-05). Statistical changes in diastolic blood pressure were not found (Fig. 3) .
Discussion
These results confirm other preliminary reports which 
